Diabetes, overweight and obesity
Conditions
Interventions
Mogroside V group :Mogroside V solution in the first week
Erythritol solution in the second week
Sucrose solution in the third week
Sucrose group:Sucrose solution in the first week
Mogroside V solution in the second week
Erythritol solution in the third week
Erythritol group:Erythritol solution in the first week
Sucrose solution in the second week
Mogroside V solution in the third week
Sponsors
Third Medical Center, PLA General Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 36 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ?Healthy adults with a normal body weight (BMI: 18.5-23.9kg/m2); ? Nationality: unlimited; ? Gender: female; ? Age: 18-36 years old; ?All participants volunteered to join the trial, all women had normal menstrual cycles, and the study was conducted only during the first 10 days of their menstrual cycle. ?A laboratory examination, medical and psychiatric history, and physical and neurological examination were taken, which showed that there was no evidence of present or past psychiatric, medical or neurological disease. ? No signs of an eating disorder.
Exclusion criteria
Exclusion criteria: Exclusion criteria: ?BMI 24 kg/m2; ? Current smokers, have a history of alcohol consumption or current alcohol consumption of more than 4 units/day; ?A history of medical or surgical events that could have had a significant impact on the findings of the study, such as metabolic or endocrine disorders or any gastrointestinal disorders; Irregular eating habits; Being on a self-imposed or medically prescribed diet; Use of drugs (other than aspirin or paracetamol); Claustrophobia; Diabetes mellitus; Severe diabetes, hypertriglyceridemia, cerebrovascular disease and other serious diseases requiring immediate treatment; Metal implants or metal objects that cannot be removed from the body (e.g., piercings, hearing AIDS or braces); ? Patients with serious primary diseases such as liver, kidney and hematopoietic system and mental illness; ? Pregnant or lactating women; ? Allergic constitution and allergic to the test drug; ? is participating in other nutritional intervention researchers; ?Any active (viral, bacterial, fungal) infection currently being treated or any infection requiring 7 or more days of intravenous antibiotics in the past 6 weeks, or any active infection requiring oral antibiotics in the past 4 weeks. ? Patients with untreated chronic active hepatitis B, or chronic hepatitis B virus carriers with =1000 copies /ml of HBV DNA, or active hepatitis C; ? Patients who have participated in other clinical trials and used investigational drugs within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fMRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI;VAS;24-hour dynamic blood glucose monitoring;Ghrelin;Leptin;GIP;CCK;PYY;GLP-1;FINS;Live function;Renal function;Hight;Waistline;Body composition;Blood pressure; | — |
Countries
China
Contacts
Public ContactQiao Chen
Third Medical Center, PLA General Hospital
Outcome results
None listed